FDA Approves Alexion’s Voydeya as Add-on Treatment for Adults with Extravascular Hemolysis

Treatment approved in combination with ravulizumab or eculizumab, representing minority demographic still suffering after receiving C5 inhibitor therapy for extravascular haemolysis.